gemfibrozil has been researched along with mycophenolic acid in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fujiwara, R; Koga, T; Nakajima, M; Yokoi, T | 1 |
| Deguchi, T; Furuta, Y; Fusegawa, K; Hirouchi, M; Igeta, K; Ikenaga, H; Iwasaki, M; Izumi, T; Kurihara, A; Murata, S; Okazaki, O; Suzuki, N; Watanabe, N | 1 |
| Galetin, A; Gill, KL; Houston, JB | 1 |
| Boido, V; Collu, G; Delogu, I; Giliberti, G; La Colla, P; Loddo, R; Novelli, F; Sparatore, A; Sparatore, F; Tasso, B; Tonelli, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kashihara, M; Mizuguchi, M; Yokoyama, T | 1 |
1 review(s) available for gemfibrozil and mycophenolic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for gemfibrozil and mycophenolic acid
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Comet Assay; DNA Damage; Glucuronides; Glucuronosyltransferase; HEK293 Cells; Hepatocytes; Humans; Kidney | 2011 |
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Area Under Curve; Cytochrome P-450 Enzyme System; Dogs; Drug Evaluation, Preclinical; Glucuronides; Glucuronosyltransferase; Half-Life; Humans; Macaca fascicularis; Male; Mice; Pharmaceutical Preparations; Predictive Value of Tests; Rats; Rats, Sprague-Dawley; Species Specificity | 2011 |
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
Topics: Adult; Aged; Female; Glucuronides; Glucuronosyltransferase; Humans; In Vitro Techniques; Intestinal Mucosa; Intestines; Kidney; Liver; Male; Metabolic Clearance Rate; Microsomes; Middle Aged; Organ Specificity; Pharmaceutical Preparations; Predictive Value of Tests; Protein Binding; Serum Albumin, Bovine; Substrate Specificity; Young Adult | 2012 |
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
Topics: Animals; Antiviral Agents; Cell Line; Cell Survival; Cricetinae; DNA Viruses; Dogs; Enterovirus B, Human; Humans; RNA Viruses; Structure-Activity Relationship; Triazoles; Virus Replication | 2015 |
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
Topics: Amyloid Neuropathies, Familial; Anthelmintics; Bithionol; Crystallography, X-Ray; Drug Repositioning; Humans; Prealbumin; Thermodynamics; Triclabendazole | 2021 |